Enanta Pharmaceuticals to Present at the Deutsche Bank 2014 BioFEST
November 21 2014 - 8:00AM
Business Wire
Presentation to be Webcast on December 1 at
10:25 A.M. ET
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and
development-focused biotechnology company dedicated to creating
small molecule drugs primarily in the infectious disease field,
today announced that Jay R. Luly, Ph.D., President and Chief
Executive Officer, will participate in a fireside chat, or question
and answer session, with investors December 1, 2014 at 10:25 a.m.
ET during the Deutsche Bank 2014 BioFEST conference in Boston.
A live webcast and replay of the question and answer session can
be accessed by visiting the “Calendar of Events” section on the
“Investors” page of Enanta’s website at www.enanta.com. The replay
webcast will be available following the presentation and will be
archived for approximately 30 days.
About Enanta
Enanta Pharmaceuticals is a research and development-focused
biotechnology company that uses its robust chemistry-driven
approach and drug discovery capabilities to create small molecule
drugs primarily in the infectious disease field. Enanta is
discovering, and in some cases developing, novel inhibitors
designed for use against the hepatitis C virus (HCV). These
inhibitors include members of the direct acting antiviral (DAA)
inhibitor classes – protease (partnered with AbbVie), NS5A and
nucleotide polymerase – as well as a host-targeted antiviral (HTA)
inhibitor class targeted against cyclophilin. Additionally, Enanta
has a Bicyclolide antibiotic in early clinical development with the
National Institute of Allergy and Infectious Diseases (NIAID) for
the potential treatment of multi-drug resistant bacterial
infections.
Investor ContactEnanta Pharmaceuticals, Inc.Carol Miceli,
617-607-0710cmiceli@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Apr 2024 to May 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From May 2023 to May 2024